1 - 5 out of 5Page size: 10
  1. 2021

  2. Changes in peripheral blood compounds following psychopharmacological treatment in drug-naïve first-episode patients with either schizophrenia or major depressive disorder: A meta-analysis

    Çakici, N., Sutterland, A. L., Penninx, B. W. J. H., de Haan, L. & van Beveren, N. J. M., Mar 2021, In: Psychological medicine. 51, 4, p. 538-549 12 p.

    Research output: Contribution to journal › Review article › Academic › peer-review

  3. 2020

  4. Reply to interleukin-6 in schizophrenia: Cause of death matters

    Çakici, N., Sutterland, A. L., Penninx, B. W. J. H., de Haan, L. & van Beveren, N. J. M., Nov 2020, In: Brain, behavior, and immunity. 90, p. 383-384 2 p.

    Research output: Contribution to journal › Letter › Academic › peer-review

  5. Altered peripheral blood compounds in drug-naïve first-episode patients with either schizophrenia or major depressive disorder: a meta-analysis

    Çakici, N., Sutterland, A. L., Penninx, B. W. J. H., Dalm, V. A., de Haan, L. & van Beveren, N. J. M., Aug 2020, In: Brain, behavior, and immunity. 88, p. 547-558 12 p.

    Research output: Contribution to journal › Article › Academic › peer-review

  6. 2019

  7. An update on the efficacy of anti-inflammatory agents for patients with schizophrenia: A meta-analysis

    Çakici, N., van Beveren, N. J. M., Judge-Hundal, G., Koola, M. M. & Sommer, I. E. C., 1 Oct 2019, In: Psychological medicine. 49, 14, p. 2307-2319

    Research output: Contribution to journal › Article › Academic › peer-review

  8. Increased serum levels of leptin and insulin in both schizophrenia and major depressive disorder: A cross-disorder proteomics analysis

    Çakici, N., Bot, M., Lamers, F., Janssen, T., van der Spek, P. J., de Haan, L., Bahn, S., Penninx, B. W. J. H. & van Beveren, N. J. M., Jul 2019, In: European neuropsychopharmacology. 29, 7, p. 835-846

    Research output: Contribution to journal › Article › Academic › peer-review

ID: 4395715